The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

Abstract Background Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genom...

Full description

Bibliographic Details
Main Authors: Kenneth M. K. Mark, Frederick S. Varn, Matthew H. Ung, Feng Qian, Chao Cheng
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Breast cancer
Neoadjuvant chemotherapy
ChIP-seq
Transcription factor
E2F4
Pathologic complete response
Online Access:http://link.springer.com/article/10.1186/s12885-017-3297-2

Internet

http://link.springer.com/article/10.1186/s12885-017-3297-2

Similar Items